RECENT NEWS

Clinical trial data demonstrates how Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platforms can identify predictive biomarkers in immunotherapy and targeted therapy-treated melanoma patients.

A new policy paper published by the Medicines and Healthcare products Regulatory Agency (MHRA) commits the UK to major reform in treatments for rare diseases, with a new rulebook for rare therapies being prepared for publication next year.

A new genomic method has identified 145 participants from the 100,000 Genomes Project with a complex genetic change linked to a rare condition, providing some with an explanation for their rare condition for the first time and others with a more precise diagnosis.

Immunohistochemistry firm Biocare Medical and Hamamatsu Corporation, an innovator in imaging technologies, have announced a strategic collaboration to accelerate innovation in the rapidly expanding field of spatial biology.

The influenza season has hit the NHS more than a month earlier than usual, with cases three times higher than this time last year; as shown by the UK Health Security Agency (UKHSA) latest surveillance data.

Ten pioneering health start-ups are tackling some of the world’s toughest healthcare challenges, from lung cancer to eye disease, at the Science and Technology Facilities Council’s (STFC) Daresbury Laboratory.

Professor Jacob George has been appointed as the first Chief Medical and Scientific Officer for the Medicines and Healthcare products Regulatory Agency (MHRA).

A new genetic test could be introduced into NHS screening pathways to target those most at risk of abdominal aortic aneurysm (AAA).

Roche has received the CE mark for its Elecsys Dengue Ag test – a high-throughput, fully automated immunoassay to be used as an aid in the diagnosis of an acute dengue virus infection.

Primerdesign (part of the Novacyt Group), a company focused on the design, manufacture, validation and supply of real-time PCR kits and reagents, has signed a distribution agreement with Scientific Laboratory Supplies (SLS).

EazeBio, a biotechnology company focused on developing scalable, patient-centred solutions, has announced a strategic partnership with the University of California, Santa Cruz (UC Santa Cruz) to co-develop an innovative cortisol biosensor for stress and metabolic health testing.

Lab Innovations, the UK’s biggest trade show event for the laboratory industry, has published a new report examining how artificial intelligence (AI) is being applied in UK laboratories.

Grundium, a specialist in digital imaging for pathology, and Washington University, St. Louis (WashU), have shown that Grundium’s technology matches the diagnostic accuracy of traditional methods for rapid on-site evaluation while decreasing turnaround times and improving patient care.

A new study has shown that Dragonfly, a low-cost, rapid, molecular testing platform is successfully able to detect asymptomatic malaria infections.

Image management system and workflow platform for digital pathology PathPresenter has announced that its Clinical Viewer has met the requirements of the EU In Vitro Diagnostic Regulation (IVDR 2017/746) and can now bear the CE mark. This certification clears it for clinical use in primary diagnosis in Europe.

Researchers at VIB, a leading Belgian life sciences research institute, will conduct on-site testing of CosmoSort, first spatial biology technology to isolate precise cells and tissue regions, without compromising surrounding tissue.

Chandra Mohan, an international expert and pioneer in lupus research at the University of Houston, reports that urine samples can indicate lupus nephritis in a non-invasive manner, without the need for repeat and painful renal biopsies.

Tickets are now available for ‘The Power to Disrupt Through Diagnostics’ the next POCT Innovators one-day conference, which takes place Monday 15 December at London’s National Army Museum.

NHS England has promised an end to short term thinking with the release of a new planning framework document, which also sets out more detail on shifting more healthcare to community settings.

Life science reagents company ProImmune has opened its new global headquarters building at Oasis Park, Oxford, enabling significant expansion of its operations and capacity to serve its global client base.